Nature of tumour rejection antigens in ovarian cancer |
| |
| Authors: | Muzamil Y. Want Amit A. Lugade Sebastiano Battaglia Kunle Odunsi |
| |
| Affiliation: | Center For Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA |
| |
| Abstract: | Major progress in the analysis of human immune responses to cancer has been made through the molecular characterization of human tumour antigens. The development of therapeutic strategies for eliciting immune‐mediated rejection of tumours has accelerated due to the elucidation of the molecular basis for tumour cell recognition and destruction by immune cells. Of the various human tumour antigens defined to date in ovarian cancer, the cancer‐testis (CT) family of antigens have been studied extensively preclinically and clinically because of their testis‐restricted expression in normal tissues and ability to elicit robust immune responses. Recent developments in cancer sequencing technologies offer a unique opportunity to identify tumour mutations with the highest likelihood of being expressed and recognized by the immune system. Such mutations, or neoantigens, could potentially serve as specific immune targets for T‐cell‐mediated destruction of cancer cells. This review will highlight current work in selecting tumour rejection antigens in ovarian cancer for improving the efficacy of immunotherapy. |
| |
| Keywords: | antigen immunotherapy next‐generation sequencing ovarian cancer |
|
|
